Document 1166
 DOCN  M94A1166
 TI    Didanosine-induced ejaculatory dysfunction.
 DT    9412
 AU    Mayo J; Collazos J; Martinez E; Section of Infectious Diseases, Hospital
       de Galdakao, Vizcaya,; Spain.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):194 (abstract no. PB0791). Unique
       Identifier : AIDSLINE ICA10/94371409
 AB    Ejaculatory dysfunction was reported by two patients two and three
       months respectively after treatment with didanosine in the absence of
       other manifestations of neurotoxicity. Patient 1. A 30-year-old man,
       HIV-1-infected IVDU, without previous opportunistic infections, with a
       CD4 count of 0.3 x 10(9)/L (CDC group A2), and intolerant to zidovudine,
       was treated with didanosine 200 mg every 12 h. Eight weeks later, the
       patient reported a marked delay in ejaculation with normal libido and
       penile erection. He denied other symptoms, intake of other drugs or
       abuse of illicit drugs when symptoms developed. No evidence of
       peripheral neuropathy was found. Didanosine was discontinued and the
       dysfunction resolved whithin two months. Patient 2. A 31-year-old man,
       formerly IVDU, infected with HIV-1, with previous P. carinii pneumonia,
       tuberculosis and thrush, had a CD4 count of 0.03 x 10(9)/L (CDC group
       C3). Because of intolerance to zidovudine he was treated with didanosine
       200 mg every 12 h. Three months later the patient noticed inability to
       ejaculate despite normal libido and penile erection. He was also
       receiving inhaled pentamidine monthly and fluconazole weekly. He did not
       report symptoms suggestive of pheripheral neuropathy and physical
       examination was normal. Didanosine is being continued according to the
       patient's wishes and the ejaculatory dysfunction remains unchanged.
 DE    Adult  Case Report  Didanosine/*ADVERSE EFFECTS/THERAPEUTIC USE
       Ejaculation/*DRUG EFFECTS  Human  HIV Infections/COMPLICATIONS/DRUG
       THERAPY  *HIV-1  Male  Substance Abuse, Intravenous/COMPLICATIONS
       MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).